Blood test can predict Alzheimer's progression and treatment timing, study finds

A new study offers hope for predicting Alzheimer's disease progression and identifying the prime time for treatment with newly developed drugs. Researchers have found that a simple blood test can forecast the optimal window for these therapies, which aim to slow the disease by removing amyloid buildup in the brain.

The key lies in measuring levels of a specific protein, phosphorylated tau217 (p-tau217), in the blood. According to the joint research by professors from Yonsei University Gangnam Severance Hospital and Wonju Severance Christian Hospital, along with C2N Diagnostics in the U.S., these blood levels serve as a crucial indicator of amyloid and tau protein accumulation in the brain. Alzheimer's disease is characterized by the slow buildup of amyloid proteins over decades, accompanied by the tangling of tau proteins within nerve cells.

This discovery is significant because current Alzheimer's drugs are most effective when administered before cognitive function severely declines. The ability to accurately predict the "golden period" for treatment through a readily available blood test could revolutionize early intervention strategies. This approach bypasses the need for costly and complex equipment, making early diagnosis and timely treatment more accessible.